Skip to main content

Advertisement

Table 1 Characteristics of the patient population

From: Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis

  Mean ± SD or n (percent) Median (range)
Age, years 62.7 ± 12.4 64.5 (31~85)
Disease duration, years 13.6 ± 11.5 11.25 (0.4~64.3)
Women 140 patients (82.4%)  
Steinbrocker‘s stage, I/II/III/IV 23 (13.5%)/53 (31.2%)/27 (15.9%)/67 (39.4%)  
Steinbrocker’s class, 1/2/3/4 41 (24.1%)/103 (60.6%)/25 (14.7%)/1 (0.01%)  
Rheumatoid factor positive 133 (78.2%)  
Anti-citrullinated protein antibody positive 135 (79.4%)  
C-reactive protein, mg/dl 0.61 ± 1.13 0.1 (0~5.4)
Erythrocyte sedimentation rate, mm/h 25.4 ± 21.1 18.5 (0~117)
Tender joint count, 0 to 28joints 1.1 ± 2.0 0 (0~14)
Swollen joint count, 0 to 28joints 1.2 ± 1.7 0 (0~9)
Patient’s global assessment, 0 to 100 mm 36.8 ± 26.3 32 (1~100)
Evaluator’s global assessment, 0 to 100 mm 14.6 ± 15.1 10 (0~73)
Disease activity score in 28 joints at endpoint 3.05 ± 1.22 2.94 (0.00~5.90)
Simplified disease activity index at endpoint 7.99 ± 6.51 5.90 (0.20~30.40)
Clinical disease activity index at endpoint 7.37 ± 5.97 5.75 (0.20~28.00)
Health Assessment Questionnaire disability index, 0 to 3 0.90 ± 0.76 0.8125 (0~3)
Sharp/van der Heijde score at baseline 109.5 ± 101.1 77.5 (1~398)
Sharp/van der Heijde score at endpoint 112.7 ± 101.6 79.5 (2~401)
Annual change of Sharp/van der Heijde score 3.6 ± 7.9 1 (− 8~58)
Use of glucocorticoid 76 (44.7%)  
Use of methotrexate 141 (70.6%)  
Use of biologics 62 (36.5%)  
 TNF inhibitors 40 (23.5%)  
 Tocilizumab 12 (7.1%)  
 Abatacept 10 (5.9%)  
  1. Data representing the demographic characteristics of the 170 patients. Data are presented as means ± S.D. or n (percent) and median (range)